Arthur T. Sands - 11 Feb 2025 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
President, CEO, Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Arthur T. Sands
Issuer symbol
NRIX
Transactions as of
11 Feb 2025
Net transactions value
$0
Form type
4
Filing time
13 Feb 2025, 16:12:35 UTC
Previous filing
15 Feb 2024
Next filing
10 Feb 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +450,000 $0.000000 450,000 11 Feb 2025 Common Stock 450,000 $17.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning March 11, 2025, until the option is fully vested on February 10, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date.